Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.25
Bid: 10.50
Ask: 12.00
Change: 2.40 (26.67%)
Spread: 1.50 (14.286%)
Open: 9.00
High: 11.40
Low: 9.00
Prev. Close: 9.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

2 Mar 2020 11:45

RNS Number : 6762E
Cantor Fitzgerald Europe
02 March 2020
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cantor Fitzgerald Europe

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Redx Pharma plc

(d) Date dealing undertaken:

28th February 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

REDX ORD 1P

Purchases

50,000

7.5 GBX

7.5 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Nil

Nil

Nil

Nil

Nil

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Nil

Nil

Nil

Nil

Nil

Nil

Nil

Nil

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Nil

Nil

Nil

Nil

Nil

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Nil

Nil

Nil

Nil

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

02nd March 2020

Contact name:

Andy Voong

Telephone number:

0207 894 7798

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFZGGFGZKGGZM
Date   Source Headline
28th Jan 20207:00 amRNSStatement re Rule 2.6 Extension
24th Jan 202011:05 amRNSHolding(s) in Company
24th Jan 20209:40 amRNSHolding(s) in Company
23rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Jan 20208:32 amRNSForm 8.3 - Redx Pharma plc
22nd Jan 20205:04 pmRNSPaul John Blackmore - Form 8.3 - RedX Pharma
22nd Jan 202012:49 pmRNSForm 8.3 - RedX Pharma PLC
22nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
21st Jan 20201:23 pmRNSResult of General Meeting
16th Jan 20209:25 amRNSForm 8.3 - Redx Pharma plc
15th Jan 20204:20 pmRNSForm 8.3 - Redx Pharma PLC
15th Jan 20203:17 pmRNSForm 8.3 - Redx Pharma Plc
15th Jan 20202:57 pmRNSForm 8.3 - Redx Pharma plc
10th Jan 20207:56 amRNSForm 8.3 - Redx Pharma plc
9th Jan 20202:14 pmRNSPublic Opening Position Disclosure
9th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
9th Jan 20207:00 amRNSRXC007 nominated as drug development candidate
7th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
6th Jan 20202:16 pmRNSForm 8.3 - Redx Pharma
6th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Jan 20204:14 pmRNSPosting of Circular to Shareholders
3rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Jan 20202:44 pmRNSForm 8.3 - Redx Pharma plc
2nd Jan 202012:57 pmGNWForm 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC
2nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
31st Dec 20197:00 amRNSLoan Capitalisation, GM Notice and Possible Offer
19th Nov 20197:00 amRNSRedx & Medicines Discovery Catapult awarded grant
7th Nov 20193:30 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSRXC006 poster presentation at ERS Congress
19th Aug 20197:00 amRNSFirst cohort of patients dosed in RXC004 study
18th Jul 201910:24 amEQSHardman & Co Research: RedX Pharma (REDX): Pan-RAF agreement strengthens balance sheet
11th Jul 20191:41 pmEQSHardman & Co Research: Redx Pharma (REDX): Phase I trial resumed
10th Jul 20197:00 amRNSSale of pan-RAF inhibitor programme
10th Jun 20197:01 amRNSInterim Results for six months ended 31 March 2019
10th Jun 20197:00 amRNSShort-term Debt Funding Secured
3rd May 201911:34 amRNSUpdate on Plans to Strengthen Balance Sheet
29th Mar 20197:00 amRNSRedx to present two posters at AACR 2019
28th Feb 20197:00 amRNSIssue of Warrants and Change to Lease Agreement
14th Feb 20197:00 amRNSDirectorate Update
12th Feb 20197:00 amRNSNew in vivo data on ROCK2
6th Feb 201911:25 amRNSReceipt of Outstanding Loan
31st Jan 20197:00 amRNSDeinove return rights to Redx Programme
23rd Jan 201911:25 amRNSResults of Annual General Meeting
21st Jan 20197:00 amRNSRXC004 Trial Approval
10th Jan 20192:05 pmRNSSecond Price Monitoring Extn
10th Jan 20192:00 pmRNSPrice Monitoring Extension
3rd Jan 20197:00 amRNSRedx to present at 2019 Biotech Showcase event
28th Dec 201811:47 amRNSPublication of Annual Report and Accounts
30th Nov 20188:45 amEQSHardman & Co Research: RedX Pharma (REDX): RXC006: First fibrosis development candidate
30th Nov 20187:00 amRNSFirst RXC006 data for treatment of fibrosis

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.